134 related articles for article (PubMed ID: 29464061)
1. Natural and molecular history of prolactinoma: insights from a
Bernard V; Villa C; Auguste A; Lamothe S; Guillou A; Martin A; Caburet S; Young J; Veitia RA; Binart N
Oncotarget; 2018 Jan; 9(5):6144-6155. PubMed ID: 29464061
[TBL] [Abstract][Full Text] [Related]
2. Pituitary prolactin-secreting tumor formation: recent developments.
Xu RK; Wu XM; Di AK; Xu JN; Pang CS; Pang SF
Biol Signals Recept; 2000; 9(1):1-20. PubMed ID: 10686432
[TBL] [Abstract][Full Text] [Related]
3. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms.
Schuff KG; Hentges ST; Kelly MA; Binart N; Kelly PA; Iuvone PM; Asa SL; Low MJ
J Clin Invest; 2002 Oct; 110(7):973-81. PubMed ID: 12370275
[TBL] [Abstract][Full Text] [Related]
4. Association of prolactin receptor (PRLR) variants with prolactinomas.
Gorvin CM; Newey PJ; Rogers A; Stokes V; Neville MJ; Lines KE; Ntali G; Lees P; Morrison PJ; Singhellakis PN; Malandrinou FC; Karavitaki N; Grossman AB; Karpe F; Thakker RV
Hum Mol Genet; 2019 Mar; 28(6):1023-1037. PubMed ID: 30445560
[TBL] [Abstract][Full Text] [Related]
5. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
6. Germline Prolactin Receptor Mutation Is Not a Major Cause of Sporadic Prolactinoma in Humans.
Bernard V; Bouilly J; Beau I; Broutin I; Chanson P; Young J; Binart N
Neuroendocrinology; 2016; 103(6):738-45. PubMed ID: 26641246
[TBL] [Abstract][Full Text] [Related]
7. Genomic characterization of human and rat prolactinomas.
Tong Y; Zheng Y; Zhou J; Oyesiku NM; Koeffler HP; Melmed S
Endocrinology; 2012 Aug; 153(8):3679-91. PubMed ID: 22635680
[TBL] [Abstract][Full Text] [Related]
8. CEBPD suppresses prolactin expression and prolactinoma cell proliferation.
Tong Y; Zhou J; Mizutani J; Fukuoka H; Ren SG; Gutierrez-Hartmann A; Koeffler HP; Melmed S
Mol Endocrinol; 2011 Nov; 25(11):1880-91. PubMed ID: 21980073
[TBL] [Abstract][Full Text] [Related]
9. Pathology of prolactinomas: any predictive value?
Lopes MBS
Pituitary; 2020 Feb; 23(1):3-8. PubMed ID: 31641970
[TBL] [Abstract][Full Text] [Related]
10. Differences in prolactin receptor (PRLR) in mouse and human fallopian tubes: evidence for multiple regulatory mechanisms controlling PRLR isoform expression in mice.
Shao R; Nutu M; Weijdegård B; Egecioglu E; Fernandez-Rodriguez J; Tallet E; Goffin V; Ling C; Billig H
Biol Reprod; 2008 Oct; 79(4):748-57. PubMed ID: 18596217
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
12. [Melatonin inhibits the proliferation of pituitary prolactin-secreting tumor by suppressing the enhancer elements mutation of PRL gene in the rat].
Gao L; Yang QH; Xu RK
Sheng Li Xue Bao; 2005 Jun; 57(3):319-27. PubMed ID: 15968426
[TBL] [Abstract][Full Text] [Related]
13. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
14. [Prolactin and its receptor: From animal models to pituitary pathophysiology].
Begon E; Bernard V
Biol Aujourdhui; 2022; 216(3-4):105-110. PubMed ID: 36744975
[TBL] [Abstract][Full Text] [Related]
15. Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas.
McAndrew J; Paterson AJ; Asa SL; McCarthy KJ; Kudlow JE
Endocrinology; 1995 Oct; 136(10):4479-88. PubMed ID: 7664668
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
17. Gender-related differences in prolactin secretion in pituitary prolactinomas.
Nishioka H; Haraoka J; Akada K; Azuma S
Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
[TBL] [Abstract][Full Text] [Related]
18. Lost to Follow-Up: Complications of an Invasive Giant Prolactinoma.
Blackmon MM; Gilbert AR; Floyd J; Hafeez S; Seifi A
Cureus; 2020 Aug; 12(8):e9763. PubMed ID: 32944476
[TBL] [Abstract][Full Text] [Related]
19. Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?
Williams TA; Dietz AS; Theodoropoulou M; Riester A; Fischer E; Burrello J; Treitl M; Geyer L; Veglio F; Bidlingmaier M; Schopohl J; Beuschlein F; Mulatero P; Reincke M
J Clin Endocrinol Metab; 2015 Sep; 100(9):E1262-9. PubMed ID: 26176803
[TBL] [Abstract][Full Text] [Related]
20. The permissive role of prolactin as a regulator of luteinizing hormone action in the female mouse ovary and extragonadal tumorigenesis.
Bachelot A; Carré N; Mialon O; Matelot M; Servel N; Monget P; Ahtiainen P; Huhtaniemi I; Binart N
Am J Physiol Endocrinol Metab; 2013 Oct; 305(7):E845-52. PubMed ID: 23921141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
